Shah Preetam
- SEC CIK
- 0001787403
No open-market purchases or sales filed in the past year.
Current role at each company
- ELTX Elicio Therapeutics, Inc.See Remarksas of Jul 17, 2026
- CDTX Cidara Therapeutics, Inc.Chief Financial Officeras of Oct 2, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Shah Preetam as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
CDTX Cidara Therapeutics, Inc.
Chief Financial Officer4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2024 (view filing) | Mar 11 | 1 day | Shah PreetamCFO & CBO | SSale | −18.9K | $0.67 | −$12.7K | −7.7%227.2K after | |
| Mar 13, 2023 (view filing) | Mar 13 | Same day | Shah PreetamCFO & CBO | SSale | −6.65K | $1.53 | −$10.2K | −4.3%148.1K after | |
| Sep 19, 2022 (view filing) | Sep 19 | Same day | Shah PreetamCFO & CBO | SSale | −15.6K | $0.77 | −$12.0K | −9.4%150.8K after | |
| Nov 15, 2021 (view filing) | Nov 12 | 3 days | Shah PreetamCFO & CBO | PPurchase | +20.0K | $1.54 | +$30.8K | New position20.0K after |